We have located links that may give you full text access.
Clinical usefulness of anti-cell membrane DNA autoantibodies in serology negative systemic lupus erythematosus.
Malaysian Journal of Pathology 2022 April
INTRODUCTION: Systemic lupus erythematosus (SLE) diagnosis is dependent on the detection of serum autoantibodies. To date, there is no autoantibody highly sensitive and specific enough to be considered as a gold standard. This study aimed to determine the diagnostic usefulness of anti-cmDNA antibodies which found to be associated with SLE.
MATERIALS AND METHODS: Serum samples from 83 SLE, 86 other connective tissue diseases (OCTD) and 61 healthy subjects were randomly selected for the study. The OCTD cases included 56 rheumatoid arthritis, 12 scleroderma, 10 Sjogren's syndrome and 8 mixed connected tissue diseases. All samples were assayed for anti-cmDNA by indirect immunofluorescence assay (IFA) using Raji cells as substrate. SLE samples were also tested for antidsDNA and anti-Sm antibodies using enzyme-immunoassays.
RESULTS: Anti-cmDNA positivity was highest in SLE (55.4%) compared to OCTD (9.3%) and healthy subjects (0%). It was 100% specific at differentiating SLE from healthy subjects and 90.7% specific at differentiating SLE from OCTD. There were no significant differences in the sensitivity (55.4%) of anti-cmDNA at differentiating SLE from OCTD and healthy groups. Anti-cmDNA was present in 52.9% of SLE samples negative for standard SLE-specific autoantibodies. It was detected in 7 (36.8%) of anti-dsDNA, 25 (52.1%) of anti-Sm and 5 (31.3%) of both anti-Sm and anti-dsDNA negative samples. Anti-cmDNA positive SLE was significantly associated with arthritis (p=0.019).
CONCLUSION: The high specificity of anticmDNA detection by IFA makes it an excellent diagnostic test for SLE. Anti-cmDNA is also useful for identifying SLE with negative anti-dsDNA or/and anti-Sm antibodies.
MATERIALS AND METHODS: Serum samples from 83 SLE, 86 other connective tissue diseases (OCTD) and 61 healthy subjects were randomly selected for the study. The OCTD cases included 56 rheumatoid arthritis, 12 scleroderma, 10 Sjogren's syndrome and 8 mixed connected tissue diseases. All samples were assayed for anti-cmDNA by indirect immunofluorescence assay (IFA) using Raji cells as substrate. SLE samples were also tested for antidsDNA and anti-Sm antibodies using enzyme-immunoassays.
RESULTS: Anti-cmDNA positivity was highest in SLE (55.4%) compared to OCTD (9.3%) and healthy subjects (0%). It was 100% specific at differentiating SLE from healthy subjects and 90.7% specific at differentiating SLE from OCTD. There were no significant differences in the sensitivity (55.4%) of anti-cmDNA at differentiating SLE from OCTD and healthy groups. Anti-cmDNA was present in 52.9% of SLE samples negative for standard SLE-specific autoantibodies. It was detected in 7 (36.8%) of anti-dsDNA, 25 (52.1%) of anti-Sm and 5 (31.3%) of both anti-Sm and anti-dsDNA negative samples. Anti-cmDNA positive SLE was significantly associated with arthritis (p=0.019).
CONCLUSION: The high specificity of anticmDNA detection by IFA makes it an excellent diagnostic test for SLE. Anti-cmDNA is also useful for identifying SLE with negative anti-dsDNA or/and anti-Sm antibodies.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app